Featured Poster: Combining the 31-Gene Expression Profile Test for Cutaneous Melanoma with the American Joint Committee on Cancer Staging Identifies the Highest-Risk Patients with Stage I-II Disease
In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Hyams and colleagues explore use of the 31-GEP test to stratify risks in cutaneous melanoma
By Dermsquared Editorial Team | June 16, 2023
Although stage I-II melanomas are usually considered low risk, the majority of melanoma-associated deaths occur in patients diagnosed with these malignancies given the absolute number of cases and limitations of traditional staging systems.
The 31-Gene Expression Profile (31-GEP) test is a prognostic assay that measures the level of expression of 31 genes in a melanoma to further stratify risk of recurrence, metastasis, and mortality. This poster presents data from a large (N=6301), unselected cohort from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program who were 31-GEP tested and had a negative sentinel lymph node biopsy.
Within this cohort, patients with a Class 1A result had a 97.9% 5-year melanoma-specific survival (MSS) while those with a Class 1B/2A or Class 2B result had a 95.7% and 85.8% 5-year MSS, respectively.